A Phase 3 interventional study of Semaglutide and Placebo (Semaglutide) in Diabetes Mellitus, Type 2 and Chronic Kidney Disease, sponsored by Novo Nordisk A/S. Completed at 49 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 80th largest by enrollment, is one of 10 that started in 2021, is one of 57 in phase 3, and was the 85th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 262nd largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 187 in phase 3, and was the 532nd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.
Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.
Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week.
The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations.
Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours.
The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Depending on /non-biopsy population:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).
Drug: Semaglutide
Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).
Drug: Placebo (Semaglutide)
Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)
Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)
Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Global Kidney Perfusion (MRI)
Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)
Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)
Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)
Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \> 0.5 or \< 0.5 and false discovery rate (FDR) \<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Glomerular Basement Membrane Width (Kidney Biopsy)
Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)
Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)
Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Mean Renal Artery Resistive Index (RARI) (MRI)
Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Mean Arterial Flow (MRI)
Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)
Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Albumin Excretion Rate (Urinalysis)
Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
Change in Kidney Function (Creatinine Clearance) (Urinalysis)
Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
Time frame: Baseline (week 0), End of treatment (week 52)
The trial was conducted at 31 sites in 8 countries.
| Milestone | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Started | 71 | 35 |
| Full analysis set | 71 | 35 |
| Safety analysis set | 71 | 35 |
| Completed | 58 | 34 |
| Not completed | 13 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Physician decision | 9 | 0 |
| Withdrew: Death | 1 | 1 |
Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.
| Ratio of kidney oxygenation (cortex) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral cortex | 0.98 ± 5.35 | 1.00 ± 7.39 |
| Right cortex | 0.98 ± 5.65 | 0.99 ± 7.26 |
| Left cortex | 0.98 ± 7.51 | 1.01 ± 9.12 |
Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.
| Ratio of kidney oxygenation (medulla) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral medulla | 0.99 ± 8.97 | 1.01 ± 11.37 |
| Right medulla | 0.98 ± 10.09 | 1.02 ± 10.83 |
| Left medulla | 0.99 ± 10.25 | 1.02 ± 13.02 |
Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of global kidney perfusion | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral kidney | 1.03 ± 26.43 | 0.99 ± 24.39 |
| Right kidney | 1.04 ± 27.84 | 0.98 ± 28.85 |
| Left kidney | 1.02 ± 29.25 | 1.01 ± 26.83 |
Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of kidney inflammation (cortex) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral cortex | 1.01 ± 3.78 | 1.01 ± 5.43 |
| Right cortex | 1.01 ± 3.88 | 1.01 ± 5.57 |
| Left cortex | 1.01 ± 3.93 | 1.01 ± 5.71 |
Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of kidney inflammation (medulla) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral medulla | 1.00 ± 3.56 | 1.00 ± 5.13 |
| Right medulla | 1.00 ± 3.90 | 1.01 ± 4.85 |
| Left medulla | 1.00 ± 3.69 | 1.00 ± 5.91 |
Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \> 0.5 or \< 0.5 and false discovery rate (FDR) \<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.
| log2 fold-change | Semaglutide 1.0 mg/Placebo |
|---|---|
| CNT-2, RSPO3 | 3.468216523 |
| CNT-Immune, SLC8A1-AS1 | 2.8531071 |
| EC-GC-1, KCNK6 | -1.952545192 |
| EC-GC-1, EMC10 | -2.485824696 |
| EC-GC-1, ENSG00000286145 | 1.831300888 |
| EC-GC-1, LMF1 | -1.528463786 |
| EC-GC-1, ANKUB1 | 1.783402404 |
| EC-GC-1, AHNAK | -1.368952211 |
| EC-GC-1, ENSG00000286150 | 1.318309657 |
| EC-GC-1, NSUN6 | -1.464540152 |
| EC-GC-1, TFCP2L1 | -2.24516792 |
| EC-GC-1, ENSG00000274422 | -1.860725608 |
| EC-GC-1, DPYD-AS1 | 1.996950045 |
| EC-GC-1, ENSG00000248138 | 2.110414741 |
| EC-GC-1, ACSM2B | -1.785467699 |
| EC-GC-1, CCNH | 1.033873239 |
| EC-GC-1, QTRT1 | -2.415240141 |
| EC-GC-1, CROCCP3 | -1.254541813 |
| EC-GC-1, ENSG00000251034 | 1.750285729 |
| EC-GC-1, LSAMP | -2.439268964 |
| EC-GC-1, LHX1-DT | -4.256689925 |
| EC-GC-1, ESRRG | -1.527414037 |
| EC-GC-1, CNTNAP2 | -2.377391827 |
| EC-GC-1, ENSG00000284966 | 1.665764749 |
| EC-GC-1, BICC1 | -1.445239386 |
| EC-GC-1, GNA14-AS1 | 1.192645521 |
| EC-GC-1, GUSBP11 | -1.318511642 |
| EC-GC-1, ENSG00000233783 | 1.668536087 |
| EC-GC-1, SEMA6A-AS1 | 1.183886707 |
| EC-GC-1, RBMS3-AS2 | 1.572052032 |
| EC-GC-1, ENSG00000286147 | -4.468841041 |
| EC-GC-1, LINC00342 | -1.151143461 |
| EC-GC-1, IRF3 | -1.566408786 |
| EC-GC-1, ENSG00000249207 | 1.35685803 |
| EC-GC-1, CRADD-AS1 | 1.972404772 |
| EC-GC-1, TOX3 | -2.206055055 |
| EC-GC-1, ENSG00000286458 | 1.271036656 |
| EC-GC-1, SLC12A3 | -2.531722898 |
| EC-GC-1, TALAM1 | 1.235573321 |
| EC-GC-1, PCDH17 | 1.107442597 |
| EC-GC-1, ATP13A3 | 1.078246118 |
| EC-GC-1, ENSG00000231772 | -2.382264501 |
| EC-GC-1, FBXL19 | -2.166973377 |
| EC-GC-1, ENSG00000254420 | 1.74612131 |
| EC-GC-1, SPC25 | 1.329461228 |
| EC-GC-1, SMAD4 | 1.13655744 |
| EC-GC-1, UFM1 | 1.20264148 |
| EC-GC-1, ENSG00000259564 | 2.071724947 |
| EC-GC-1, SHOC1 | 1.634369451 |
| EC-GC-1, MEF2C-AS2 | 1.753288691 |
| EC-GC-1, ENSG00000285801 | 1.440844025 |
| EC-GC-1, FAM228B | -1.22996414 |
| EC-GC-1, GLS | 0.868999317 |
| EC-GC-1, GDPD4 | -6.564026305 |
| EC-GC-1, INSYN2A | 1.759769032 |
| EC-GC-1, TNFRSF14 | -1.254004029 |
| EC-GC-1, PRX | -1.199880651 |
| EC-GC-1, PNN | -1.024604708 |
| EC-GC-1, KCNQ1OT1 | -0.794847103 |
| EC-GC-1, ACAP3 | -1.44397269 |
| EC-GC-1, BASP1-AS1 | -4.83539932 |
| EC-GC-1, RBFOX1 | -1.706411849 |
| EC-GC-1, CCDC90B-AS1 | -1.678217382 |
| EC-GC-1, ENSG00000240499 | 1.514399208 |
| EC-GC-1, LINC03076 | 1.545248095 |
| EC-GC-1, LINC01409 | -1.022992954 |
| EC-GC-1, CCT4 | 1.455396063 |
| EC-GC-1, CDC73 | 0.802691458 |
| EC-GC-1, NUMA1 | -0.931923316 |
| EC-GC-1, FLT4 | -0.935590968 |
| EC-GC-1, PDLIM5 | 0.764926487 |
| EC-GC-1, SPCS3 | 1.02068757 |
| EC-GC-1, ENSG00000250646 | 1.917331079 |
| EC-GC-1, ENSG00000258168 | 1.083991656 |
| EC-GC-1, ST8SIA4 | 0.901071433 |
| EC-GC-1, BCL2L1-AS1 | 1.262413164 |
| EC-GC-1, NRSN2-AS1 | -1.275348201 |
| EC-GC-1, STARD13-AS | 1.148054491 |
| EC-GC-1, CFLAR-AS1 | 1.168941896 |
| EC-GC-1, PRKAR1A | 1.257792414 |
| EC-GC-1, ENSG00000226239 | 1.126077043 |
| EC-GC-1, CTNNA3 | -1.819759686 |
| EC-GC-1, KCNK5 | -2.491597199 |
| EC-GC-1, ESR2 | 1.071576206 |
| EC-GC-1, SLC25A46 | 1.062235788 |
| EC-GC-1, REV3L | 0.792446528 |
| EC-GC-1, ZC2HC1C | 2.027909336 |
| EC-GC-1, ENSG00000279686 | -1.453758633 |
| EC-GC-1, ACER1 | -5.256214457 |
| EC-GC-1, MALRD1 | -2.36001857 |
| EC-GC-1, RRBP1 | -0.837125744 |
| EC-GC-1, ZNF451-AS1 | 1.853753635 |
| EC-GC-1, SHANK2 | -1.481833304 |
| EC-GC-1, ENSG00000248388 | 2.196067138 |
| EC-GC-1, KPNA5 | 0.936135624 |
| EC-GC-1, APPAT | -1.750949862 |
| EC-GC-1, PCNT | -0.932423432 |
| EC-GC-1, ENSG00000233848 | 2.752498803 |
| EC-GC-1, MORF4L2 | 1.28059543 |
| EC-GC-1, ENSG00000236283 | -1.572597604 |
| EC-GC-1, SNRNP70 | -0.883484114 |
| EC-GC-1, EXD3 | -0.805539835 |
| EC-GC-1, CNTNAP5 | -2.392758482 |
| EC-GC-1, CASR | -2.323412555 |
| EC-GC-1, ENSG00000285692 | 1.124516569 |
| EC-GC-1, WDR81 | -2.102548546 |
| EC-GC-1, ZNF160 | -0.907890266 |
| EC-GC-1, CA12 | -1.63720477 |
| EC-GC-1, MAPK8IP3 | -0.998528168 |
| EC-GC-1, ABTB3 | -2.945080572 |
| EC-GC-1, CHORDC1 | 1.047593755 |
| EC-GC-1, FREM1 | -1.948982139 |
| EC-GC-1, FXYD6-AS1 | 2.22442108 |
| EC-GC-1, SPACA6 | -1.045439073 |
| EC-GC-1, AGBL1 | -2.851170905 |
| EC-GC-2, NES | -2.451444521 |
| EC-GC-2, ADARB2 | -3.212266234 |
| EC-GC-2, SERPINB9 | 2.315559798 |
| EC-GC-2, ENSG00000274422 | -2.329265154 |
| EC-GC-2, BTNL9 | -2.01168798 |
| EC-GC-2, CPEB2 | 1.51543417 |
| EC-GC-2, TBX2 | -2.604511077 |
| EC-GC-2, ENSG00000290560 | 2.378813977 |
| EC-GC-2, CFAP54 | 1.988387042 |
| EC-GC-2, ABI3BP | 1.57362138 |
| EC-GC-2, SPACA6 | -1.724379529 |
| EC-GC-2, ADAMTSL2 | -2.009897896 |
| EC-GC-2, LZTS1 | -2.659531511 |
| EC-GC-2, ENSG00000285744 | 1.889210245 |
| EC-GC-2, ENSG00000225689 | -1.414674941 |
| EC-GC-2, LUZP2 | -4.384000321 |
| EC-GC-2, NCKAP5 | -1.592351284 |
| EC-GC-2, FAT1 | -1.855192898 |
| NKC-NKT, AGBL4 | -2.145446805 |
| NKC-NKT, TFEC | 1.989578132 |
| NKC-NKT, ENSG00000254186 | -2.913048038 |
| NKC-NKT, PDE10A | -2.170777761 |
| NKC-NKT, SHANK2 | -2.431773845 |
| PEC, RGS6 | -3.331377896 |
| PEC, AHNAK | -1.645129407 |
| PT-2, LRRC4C | -2.167101922 |
| PT-2, DSCAM | -3.104786855 |
| PT-2, RCN3 | -1.636040003 |
Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.
| Nanometer (nm) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Change in Glomerular Basement Membrane Width (Kidney Biopsy) | -72.67 ± 96.60 | -8.66 ± 206.35 |
Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of ADC (cortex) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral cortex | 1.00 ± 6.56 | 0.94 ± 11.40 |
| Left cortex | 1.01 ± 8.50 | 0.96 ± 10.48 |
| Right cortex | 0.98 ± 6.70 | 0.93 ± 12.12 |
Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of ADC (medulla) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral medulla | 0.98 ± 8.90 | 0.94 ± 13.51 |
| Left medulla | 0.99 ± 9.51 | 0.95 ± 13.41 |
| Right medulla | 0.98 ± 10.00 | 0.93 ± 13.94 |
Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.
| Ratio of RARI | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral renalartery | 0.97 ± 7.00 | 1.01 ± 6.13 |
| Right renalartery | 0.98 ± 8.38 | 1.01 ± 8.62 |
| Left renalartery | 0.97 ± 7.44 | 1.01 ± 6.43 |
Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.
| Ratio of mean arterial flow | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Bilateral renalartery | 0.96 ± 24.96 | 0.96 ± 25.06 |
| Right renalartery | 0.97 ± 30.21 | 0.95 ± 29.09 |
| Left renalartery | 0.96 ± 25.06 | 0.98 ± 27.38 |
Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
| Millimoles per day (mmol/day) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis) | -7.3 ± 71.3 | -26.9 ± 85.2 |
Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
| Milligrams per day (mg/d) | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Change in Albumin Excretion Rate (Urinalysis) | -81.9 ± 708.8 | -233.2 ± 964.8 |
Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.
| Milliliter per minute | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Change in Kidney Function (Creatinine Clearance) (Urinalysis) | 3.8 ± 26.6 | -12.6 ± 34.2 |
Collected over Up to week 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide 1.0 mg | 2/71 (2.8%) | 14/71 (19.7%) | 15/71 (21.1%) |
| Placebo | 1/35 (2.9%) | 5/35 (14.3%) | 11/35 (31.4%) |
| Event | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 4/71 | 0/35 |
| DeathGeneral disorders | 0/71 | 1/35 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/71 | 1/35 |
| Peripheral ischaemiaVascular disorders | 0/71 | 1/35 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/71 | 1/35 |
| Urinary retentionRenal and urinary disorders | 0/71 | 1/35 |
| Abdominal pain upperGastrointestinal disorders | 1/71 | 0/35 |
| AngerPsychiatric disorders | 1/71 | 0/35 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/71 | 0/35 |
| Blood creatinine increasedInvestigations | 1/71 | 0/35 |
| Event | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/71 | 4/35 |
| Diabetic retinopathyEye disorders | 4/71 | 2/35 |
| NasopharyngitisInfections and infestations | 0/71 | 2/35 |
| NauseaGastrointestinal disorders | 4/71 | 2/35 |
| Upper respiratory tract infectionInfections and infestations | 1/71 | 2/35 |
| COVID-19Infections and infestations | 4/71 | 0/35 |
| Decreased appetiteMetabolism and nutrition disorders | 4/71 | 0/35 |
Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product.
| Age, Continuous(Years) | Semaglutide 1.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 65.4 ± 9.2 | 65.1 ± 11.3 | 65.3 ± 9.9 |
| Sex: Female, Male(Participants) | Semaglutide 1.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 16 | 9 | 25 |
| Male | 55 | 26 | 81 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 1.0 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 59 | 28 | 87 |
| Unknown or Not Reported | 7 | 4 | 11 |
| Race/Ethnicity, Customized(Participants) | Semaglutide 1.0 mg | Placebo | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 2 | 0 | 2 |
| Black Or African American | 5 | 5 | 10 |
| Not Reported | 6 | 4 | 10 |
| White | 43 | 22 | 65 |
| Other | 4 | 0 | 4 |
| Asian | 11 | 4 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Apr 2021 to primary completion in Nov 2024, 42 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 42 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide